Track market-moving stories before they get noisy

Tencent Music Entertainment Group NYSE: TME reported steady first-quarter 2026 results as management highlighted growth in music-related services, rising contributions from offline performances and continued pressure from competition and AI-related copyright issues.

Tencent shares slide after Q1 misses, though AI-led ad growth, gaming gains and rising cloud demand support revenue growth.

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

Kingsoft Cloud and peers gain appeal as U.S.-China trade easing and policy shifts lift confidence in Chinese tech into 2026.

China's economy is sending mixed signals – retail sales growth in April hit its weakest level since the Covid-19 era, and broader consumer sentiment remains subdued. Yet within that fog, a sharper picture is emerging for equity investors: artificial intelligence is the one theme cutting cleanly through the noise.

U.S. PayPal users can now make purchases across China ​using WeChat Pay's QR-code merchant ‌network, Tencent Financial Technology said on Wednesday, adding the service will be rolled ​out to PayPal users in ​other markets in phases.

The biggest Chinese technology companies are underperforming the market despite the ongoing artificial intelligence boom. Xiaomi stock has plunged by 30% this year, while Tencent and Alibaba have dropped by 27% and 13%, respectively.

BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, attended the 2026 Tencent Cloud AI Industry Applications Summit in Beijing, where it showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health. The conference, themed “Agent in Action, Productivity in Motion,” brought together industry leaders, technology developers, and ecosystem partners to explore how AI agents are driving productivity and accelerating enterprise adoption of artificial intelligence.

Tencent Holdings (TCEHY) is preparing a fresh offshore debt push as the Chinese technology and gaming giant moves to raise around $3 billion in a dual-currency

Tencent (TCEHY) could produce exceptional returns because of its solid growth attributes.

The undisclosed stake in Barrick's Fourmile gold project could add up to $3 billion in value to a combined Anglo-Teck group A previously undisclosed royalty held by Teck Resources on Barrick Mining's Fourmile gold project in Nevada has strengthened the case for Anglo American PLC's (LSE:AAL) proposed merger with the Canadian miner, according to Citigroup analysts. The Globe and Mail reported this week that Teck owns a 10% net profits interest on Fourmile, a project Barrick has described as one of the most significant gold discoveries of the century, with the royalty rising to 15% once six million ounces of gold are produced.

Investors interested in Mining - Miscellaneous stocks are likely familiar with Nexa Resources S.A. (NEXA - Free Report) and Anglo American (NGLOY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Nexa Resources S.A. and Anglo American are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that NEXA has an improving earnings outlook. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

NEXA currently has a forward P/E ratio of 7.88, while NGLOY has a forward P/E of 24.23. We also note that NEXA has a PEG ratio of 0.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NGLOY currently has a PEG ratio of 0.58.

Another notable valuation metric for NEXA is its P/B ratio of 1.5. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, NGLOY has a P/B of 2.39.

Based on these metrics and many more, NEXA holds a Value grade of A, while NGLOY has a Value grade of C.

NEXA is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that NEXA is likely the superior value option right now.

Investors looking for stocks in the Mining - Miscellaneous sector might want to consider either Nexa Resources S.A. (NEXA) or Anglo American (NGLOY).

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Anglo American (NGLOY - Free Report) , a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Anglo American currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market? In order to see if NGLOY is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For NGLOY, shares are up 2.91% over the past week while the Zacks Mining - Miscellaneous industry is up 3.56% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 15.27% compares favorably with the industry's 0.32% performance as well.

Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Anglo American have risen 28.05%, and are up 85.97% in the last year. In comparison, the S&P 500 has only moved 10.8% and 30.05%, respectively.

Investors should also pay attention to NGLOY's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. NGLOY is currently averaging 446,351 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with NGLOY.

Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost NGLOY's consensus estimate, increasing from $0.73 to $1.15 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom LineTaking into account all of these elements, it should come as no surprise that NGLOY is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Anglo American on your short list.

Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.

Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.

From late 2023 to early 2024, Viking Therapeutics (VKTX +3.10%) took off like a rocket, as it seemed that the clinical-stage biotech company would become the dark-horse candidate among GLP-1 stocks.

Flash-forward two years, and significantly fewer investors hold a bullish view. Viking, which once traded for nearly $100 per share, now trades at just under $30. Before considering a purchase of this once-popular and now apparently undervalued stock, keep in mind that the company faces many hurdles in taking on competitors like Novo Nordisk and Eli Lilly.

Image source: Getty Images.

Viking Therapeutics' rise and fall In the GLP-1 wars, Novo Nordisk was the early mover, obtaining approval for Wegovy from the U.S. Food and Drug Administration in June 2021. Then Eli Lilly received FDA approval to market Zepbound in November 2023. But shortly thereafter, speculative frenzy emerged about Viking Therapeutics and its VK2735 weight-loss drug candidate.

Today's Change

(

3.10

%) $

0.86

Current Price

$

28.61

While similar to Zepbound -- both are dual agonists that bind to both GLP-1 and GIP receptors -- VK2735 demonstrated even stronger clinical trial results at the time. Betting that another pharmaceutical company would buy Viking, investors aggressively bid up its shares early in 2024. After that, however, data from subsequent trials, including reports of worse-than-expected side effects, soured public perception.

Why it's wise to stay skeptical Viking has remained a contender, but over the past two years, skepticism and uncertainty have stayed high. Its injection-based and pill-based VK2735 candidates remain at the clinical-trial stage. Meanwhile, Viking's larger competitors are making progress on new, more powerful treatments, such as Novo Nordisk's investigational dual agonist CagriSema, and Eli Lilly's triple-agonist candidate retatrutide.

By the time Viking is able to bring a weight-loss drug to market, competition could prove far more steep. That's not all. Viking has around $603 million in cash on hand, but is burning through about $114 million per quarter. To bring its drug candidates all the way to market, the company may need to eventually raise more cash, leading to share dilution.

Much suggests that Viking Therapeutics stock is "too little, too late." You may want to skip it in favor of larger but less risky GLP-1 plays.

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Viking Therapeutics, Inc. (VKTX - Free Report) closed the most recent trading day at $32.18, moving +1.64% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.05%, and the technology-dominated Nasdaq saw an increase of 0.91%.

The stock of company has risen by 1.05% in the past month, lagging the Medical sector's gain of 2.82% and the S&P 500's gain of 4.96%.

Market participants will be closely following the financial results of Viking Therapeutics, Inc. in its upcoming release. On that day, Viking Therapeutics, Inc. is projected to report earnings of -$1.21 per share, which would represent a year-over-year decline of 108.62%.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$4.67 per share and a revenue of $0 million, representing changes of -46.39% and 0%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 23.57% downward. Viking Therapeutics, Inc. presently features a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 107, this industry ranks in the top 44% of all industries, numbering over 250.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

An upcoming trial result could change how investors think about the weight-loss drug market.

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Viking Therapeutics, Inc. (VKTX - Free Report) closed the most recent trading day at $27.73, moving -5.13% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 1.62%. Elsewhere, the Dow lost 1.87%, while the tech-heavy Nasdaq lost 1.98%.

Shares of the company have depreciated by 6.67% over the course of the past month, underperforming the Medical sector's gain of 5.04%, and the S&P 500's loss of 0.03%.

The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company's earnings per share (EPS) are projected to be -$1.21, reflecting a 108.62% decrease from the same quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$4.7 per share and a revenue of $0 million, representing changes of -47.34% and 0%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Viking Therapeutics, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.72% downward. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Viking Therapeutics (VKTX +3.10%) has seen its stock stumble in recent times -- for example, it's slipped over the past year. But over five years, shares of the biotech company have climbed more than 300%. This is amid excitement about the company's potential in a market that's on track to reach nearly $100 billion in just a few years. I'm talking about the weight loss drug market.

Viking hasn't yet commercialized a drug, but it has a promising candidate in late-stage trials, so it may be very close to the finish line in this valuable market. All of this means the biotech, which specializes in developing candidates for metabolic and endocrine disease, might generate revenue -- and at significant levels -- in just a few years.

Though investors haven't rushed into the stock in recent months, this could soon change. Viking has catalysts just ahead: The company expects to report data from a maintenance dosing study of its weight loss drug candidate in the third quarter, and it aims to launch a phase 3 trial for the oral version of its candidate in the fourth quarter.

Considering this, is Viking stock going to $100? Let's find out.

Image source: Getty Images.

Blockbuster weight loss drugs We'll start with some details about Viking's lead candidate, VK2735. This is an investigational dual GLP-1/GIP receptor agonist, much like the popular drugs sold by market leaders Eli Lilly and Novo Nordisk. These drugs act on hormonal pathways involved in digestion, and as a result, they help control appetite and blood sugar levels. The Lilly and Novo drugs have become blockbusters, and demand has been consistently high for these products -- this is thanks to their efficacy, safety, and ease of use.

Though these pharma giants dominate the space, as mentioned, it is a high-growth market, so there is room for others to enter. And even if a company such as Viking doesn't take leadership -- and I wouldn't expect it to unseat a massive pharma company like Lilly or Novo -- it still could bring in blockbuster revenue. That could be quite a huge step for a young biotech.

And Viking does offer its own twist, differentiating itself from current GLP-1 drugs. At the moment, Lilly offers a dual GLP-1/GIP drug in injectable format and a GLP-1 drug in oral format. Novo's obesity drugs are GLP-1s. (Dual GLP-1/GIP drugs interact with two hormonal pathways, while GLP-1s interact with only one hormonal pathway.)

Injectable and oral formulations Viking is developing VK2735 in both injectable and oral formats. So, if approved, it would be the first dual GLP-1/GIP drug available in oral format -- and the first dual available in both injectable and oral formats. One big advantage of this is that patients can shift from one formulation to the other -- for example, starting with the oral treatment and then using the injectable for maintenance once they've reached their desired weight.

Today's Change

(

3.10

%) $

0.86

Current Price

$

28.61

The phase 3 trial for Viking's injectable is ongoing, and as mentioned, the phase 3 study for the oral formulation is set to begin later this year. We also should see data from its maintenance dosing trial in the months to come. These events could represent catalysts for the stock, which has been known to react to news. When Viking initially announced phase 2 data for VK2735 a couple of years ago, the stock soared more than 100% in one trading session.

So now, let's return to our question: Is Viking heading to $100? It reached a high of more than $94 when it announced phase 2 data in February of 2024. The stock has since given back much of that gain, and it trades today for about $27. But the average Wall Street estimate calls for it to reach more than $92 within the coming 12 months, recovering much of that territory.

The path to $100 represents a jump of more than 200%. I don't see that happening overnight like Viking's massive gain in February of 2024. But a few updates or general good news in the obesity drug market could help it along the way -- so Viking could indeed be heading to $100 in the quarters to come.

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates.

Iovance Biotherapeutics (IOVA - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on May 7, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis biotechnology company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +47.2%.

Revenues are expected to be $77.11 million, up 56.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 18.18% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Iovance Biotherapeutics?For Iovance Biotherapeutics, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -10.53%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Iovance Biotherapeutics will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Iovance Biotherapeutics would post a loss of$0.22 per share when it actually produced a loss of -$0.18, delivering a surprise of +18.18%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Iovance Biotherapeutics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAcadia Pharmaceuticals (ACAD - Free Report) , another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.04 for the quarter ended March 2026. This estimate points to a year-over-year change of -63.6%. Revenues for the quarter are expected to be $281.75 million, up 15.3% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Acadia has been revised 7.9% down to the current level. Nevertheless, the company now has an Earnings ESP of +100.00%, reflecting a higher Most Accurate Estimate.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Acadia will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.